Latest filing published 03 Mar 2026 for Organogenesis Holdings Inc.. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Lori Freedman in Organogenesis Holdings Inc., where the filings describe the role as senior executive. The record holds 14 filings, for trades running from 15 February 2022 to 18 February 2026.
The open-market record is one-sided, with 1 purchase worth €249k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 13 share grants.
The latest filing, published on 3 March 2026, reports a share grant in Organogenesis Holdings Inc. The most recent open-market purchase was published on 6 June 2025, 499 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations